The first biosimilar to Humira, adalimumab-atto (Amjevita, Amgen), is now available in the United States, Amgen announced.
Adalimumab-atto, an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody (mAb), was the first biosimilar to Humira (AbbVie) approved by the FDA in 2016, and is the first to come to market. Additional biosimilars of adalimumab are expected to come to market this year.
The active ingredient in adalimumab-atto is an anti-TNF-alpha mAb that has the same amino acid sequence